AstraZeneca PLC Earnings Dividend

AstraZeneca PLC’s revenue jumped 12.51% since last year same period to $15288Mn in the Q1 2026. On a quarterly growth basis, AstraZeneca PLC has generated -1.39% fall in its revenue since last 3-months.

AstraZeneca PLC’s net profit jumped 5.62% since last year same period to $3080Mn in the Q1 2026. On a quarterly growth basis, AstraZeneca PLC has generated 32.42% jump in its net profits since last 3-months.

AstraZeneca PLC’s net profit margin fell -6.12% since last year same period to 20.15% in the Q1 2026. On a quarterly growth basis, AstraZeneca PLC has generated 34.28% jump in its net profit margins since last 3-months.

AstraZeneca PLC’s price-to-earnings ratio after this Q1 2026 earnings stands at 27.77.

AstraZeneca PLC’s earning per share (EPS) estimates for the current quarter stand at 1.27 - a 19.98% jump from last quarter’s estimates.

AstraZeneca PLC’s earning per share (EPS) estimates for the current year stand at 1.27.

AstraZeneca PLC’s earning per share (EPS) jumped 3.61% since last year same period to 1.29 in the Q1 2026. This indicates that the AstraZeneca PLC has generated 3.61% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. AstraZeneca PLC’s return on assets (ROA) stands at 0.08.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. AstraZeneca PLC’s return on equity (ROE) stands at 0.23.

AstraZeneca PLC declared 1.6 dividend per share during the earnings announcement for Q1 2026.